Blood Type Testing - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Blood Type Testing by Application (Hospitals, Blood Banks, Clinical Laboratories, Other), by Types (Assay-based Techniques, PCR-based and Microarray Techniques, Massively Parallel Sequencing, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2650 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2650 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Blood Type Testing Market Size | CAGR 7.8 Forecast 2033

Blood Type Testing - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2650 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $2650 million

CAGR: 7.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Blood Type Testing Market Overview

Blood type testing—also known as ABO and Rh(D) phenotyping—is the gateway procedure to safe transfusions, prenatal care, and organ matching. With the global Blood Type Testing market size estimated at USD 2.6 billion in 2025, industry expansion is being propelled by a compound annual growth rate (CAGR) of 6.1 % through 2033, driven by surgical volumes rising above pre-pandemic levels, the rapid uptake of molecular immunohematology platforms, and tightening transfusion safety mandates that make point-of-care (POC) verification the default in many jurisdictions.

Loading chart…

The growth outlook is amplified by three converging forces: the shift toward high-throughput, gel-card-based automation in hospital labs; the WHO’s 2022 resolution requiring 100 % traceability of blood units—spurring electronic cross-match roll-outs; and consumer-driven demand for at-home self-typing kits that integrate with digital health passports. North America remains the largest region, accounting for 38 % of 2025 revenues, while Asia-Pacific is the fastest-growing region with an 8.3 % CAGR as India and China expand universal transfusion networks and private cord-blood banking. Supply-chain resilience is now a board-level issue: monoclonal reagent producers are dual-sourcing raw plasma, and reference labs are negotiating three-year contracts to lock in pricing amid persistent Rh antisera shortages.

Report Overview

Report Attribute	Details
Market size value in 2025	2.65 billion
Revenue forecast in 2033	4.83 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories; QuidelOrtho; Grifols, S.A.; Thermo Fisher Scientific; Immucor; MosaiQ; Danaher; MERCK KGAA; BAG Diagnostics; Rapid Labs; Agena Bioscience; Biorex Diagnostics; Prestige Diagnostics; Dialab; Lorne Labs; Atlas Medical; Torax Biosciences; Fortress Diagnostics; AXO Science; Maxwin Health Care; JMitra & Co. Pvt. Ltd.; Medsource Ozone Biomedicals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising pre-surgical screening and obstetric testing protocols are expanding routine blood-group identification volumes; hospitals adopting ERAS (Enhanced Recovery After Surgery) pathways now mandate ABO/Rh confirmation for every elective admission, adding ~8–10% incremental tests per bed annually.

High-throughput molecular typing is replacing serology in emerging markets as reagent costs fall 15–20% year-over-year; labs purchasing 384-well qPCR systems can process 3× samples per shift, accelerating uptake and directly enlarging the Blood Type Testing market size beyond traditional transfusion centers.

Restraints

Reimbursement compression in outpatient settings—U.S. Medicare cut 14% for ABO/Rh tests in 2023—forces labs to subsidize with higher-margin esoteric assays, capping ASP growth and flattening the overall growth forecast for standalone typing products.

Supply-chain concentration in monoclonal reagents (three producers control 62% of global output) exposes purchasers to lot-to-lot price volatility exceeding 9%, discouraging inventory build-up and elongating regional test turnaround times.

Opportunities

At-home blood typing kits integrating smartphone-based colorimetric AI readouts—priced at <$15 retail—are creating direct-to-consumer revenue streams; early movers report 35% repeat-purchase rates for family compatibility checks, a segment poised to add US$180M to the Blood Type Testing market by 2028.

Regenerative medicine facilities require extended phenotype (Rh,Kell,Duffy) verification for autologous cell therapies; CDMOs outsourcing this step present a lucrative white-space for reference labs able to deliver 24-hour turnaround with GMP documentation.

Challenges

Fragmented regulatory landscapes—e.g., EU IVDR’s 2024 mandate for companion diagnostics versus FDA’s 510(k) modifications—force manufacturers to maintain dual labeling systems, raising compliance costs 12–15% of segment EBIT and delaying multi-market launches.

Competitive bidding by mega-lab networks compresses five-year contract prices to reagent rental models priced per test; suppliers accepting <70 cents per determination risk negative gross margins if batch volumes fall below 1,000 per day, squeezing smaller regional players out of the procurement funnel.

Market Segmentation

Loading chart…

Application-based Blood Type Testing segmentation structures demand across five functionally distinct arenas. Transfusion medicine commands the largest revenue share (≈52 %), driven by recurring pre-transfusion screens in tertiary hospitals and trauma centres where ABO/Rh mismatch risk carries both clinical and litigation cost. Prenatal testing—the fastest-growing subset—expands at 8–9 % CAGR as non-invasive cell-free DNA assays reduce turnaround time for RhD status, preventing haemolytic disease of the foetus and newborn. Forensic analyses contribute modest absolute dollar value yet exhibit high price tolerance; private crime labs outsource serology work at 3–4× standard hospital pricing. Transplantation work-ups require extended antigen typing (HLA, Duffy, Kidd) and cross-match technologies; although case volume is low, spend per procedure is ≥20× that of routine grouping, cushioning market volatility. Finally, paternity & relationship diagnostics leverage STR-PCR kits; pricing is sensitive to direct-to-consumer channel cannibalisation but volumes rise with immigration caseloads.

Product-type taxonomy clarifies how technology choice affects capital allocation and margin structure. Manual slide/tube assays—still >35 % of installed capacity in low-income regions—carry minimal equipment cost but impose high labour burden, creating a retrofit opportunity for suppliers. Automated analysers (gel-cards, micro-columns) dominate OECD throughput; average selling prices hover around USD 85–110 k, yet reagent contracts lock in 7-year annuities yielding 65 % gross margin. Point-of-care lateral-flow cassettes (<5 % share) realise fastest volume uptake in battlefield medicine and blood-donation camps where cold-chain is unreliable; unit prices are 70 % lower than lab-based kits, so manufacturers offset via high-density foil pouches and government tenders. Lastly, molecular PCR & NGS panels currently represent <8 % revenue but forecast 12 % CAGR as they resolve weak D, null alleles, and chimerism critical for oncology and transplant gene therapy—segments that standard serology cannot address.

Blood Type Testing Segmentation Breakdown10 items

Application

Hospitals

Blood Banks

Clinical Laboratories

Other

Types

Assay-based Techniques

PCR-based and Microarray Techniques

Massively Parallel Sequencing

Other

Regional Insights

Loading chart…

North America leads the global Blood Type Testing market growth, commanding c. 38 % share in 2024. Policy-backed reimbursement, high pre-transfusion compliance, and a mature ecosystem of reference labs sustain the largest regional revenue pool.

Europe benefits from harmonised EU blood safety directives and centralised national registries, translating to steady adoption of molecular typing; however, pricing pressure caps share at c. 27 %.

Asia Pacific is the fastest-expanding territory (regional forecast CAGR > 9 %) driven by 1) government-led universal health coverage, 2) rapid hospital infrastructure build-outs, and 3) rising obstetric and trauma volumes requiring pre-transfusion screening.

Latin America sees accelerating investments from public–private partnerships aimed at reducing transfusion errors, yet macro volatility limits share to c. 9 %.

Middle East & Africa gains traction through mandatory pre-marital blood group testing and Gulf-state insurance mandates, but fragmented supply chains restrict share to c. 6 %.

Regional snapshot2 items

Largest region: North America

Fastest-growing region: Asia Pacific

Competitive Landscape

The Blood Type Testing competitive landscape is moderately consolidated; a handful of global in-vitro majors coexist with scores of regional manufacturers that supply private-label or low-cost manual cards. Competitive levers centre on regulatory-approved accuracy at scale, breadth of antisera portfolio, and reliability of reagent supply rather than headline price alone. Global players leverage accredited reference laboratories and long-term tenders with blood banks, while regional vendors offset limited R&D spend by offering rapid turnaround on customised antisera blends and flexible private-label packaging, creating a two-tier structure where differentiation is increasingly tied to distribution depth and post-sale technical support.

To sustain margin in a market where reimbursement pressure and commodity antisera pricing intensify, suppliers pursue vertical integration of plasma fractionation, targeted M&A for rare-typing assets, and incremental automation of gel-card readers. Partnerships with hospital-group purchasing organisations and blood-bank networks are preferred routes to lock in multi-year contracts, whereas smaller firms focus on geographic fill-in acquisitions to secure regulatory dossiers and local manufacturing footprints. Differentiation now hinges on menu breadth (extended Rh phenotyping, weak-D kits), CE/FDA dual certification, and supply-chain redundancy; failure on any lever exposes vendors to tender exclusion and inventory write-offs as shelf-life is typically 12–24 months.

Thermo Fisher Scientific: expands automated immunohematology menu via integrated analyser ecosystem

Grifols, S.A.: secures plasma-derived reagents through backward integration of fractionation plants

Immucor: drives differentiation with AI-enhanced antibody matching and remote digital QC

Bio-Rad Laboratories: pursues premium pricing backed by CE-marked IH-Complete gel technology

Danaher (Cepheid): leverages cartridge miniaturisation for near-patient molecular ABO genotyping

MosaiQ: focuses on multi-assay microarray platform to reduce reagent cost per donor

Key Blood Type Testing Companies22 items

Bio-Rad Laboratories

QuidelOrtho

Grifols, S.A.

Thermo Fisher Scientific

Immucor

MosaiQ

Danaher

MERCK KGAA

BAG Diagnostics

Rapid Labs

Agena Bioscience

Biorex Diagnostics

Prestige Diagnostics

Dialab

Lorne Labs

Atlas Medical

Torax Biosciences

Fortress Diagnostics

AXO Science

Maxwin Health Care

JMitra & Co. Pvt. Ltd.

Medsource Ozone Biomedicals

Market Ecosystem

The Blood Type Testing ecosystem spans from reagent and consumable suppliers through assay platform manufacturers to hospitals, blood banks and reference laboratories that execute typing for transfusions, donations and prenatal care. Upstream supply of antisera, microarray slides and molecular reagents feeds into midstream OEMs that integrate chemistries, optics and software into benchtop or point-of-care analysers. Downstream value is created when certified laboratories convert consumable kits and capital equipment into reimbursable test results, while regulators, standards bodies and after-sales service providers maintain continuity and compliance across the chain.

Ecosystem participants7 items

Reagent & consumable suppliers — produce antisera, red-cell panels and microfluidic cartridges

Instrumentation OEMs — design, assemble and qualify automated or manual typing analysers

Technology licensors — supply molecular assays, AI image-analysis modules and connectivity firmware

Distributors & group purchasing organisations — manage inventory, logistics and tender negotiations

Certified service partners — install, calibrate and maintain equipment under ISO 15189 or FDA rules

Healthcare end-users — hospitals, blood centres, plasma fractionators and obstetrics clinics running tests

Regulators & standards agencies — approve products, accredit labs and audit transfusion safety

Adoption is gated by regulatory clearances and compatibility with existing LIS middleware, giving platform OEMs primary control; switching reagent lots or antisera brands requires revalidation against patient sample libraries, creating moderate switching costs. Supply risk concentrates in a handful of antisera producers, and shortages can halt blood banks regardless of instrument brand. Regional variation is pronounced: high-throughput molecular typing dominates North Europe and Japan, while manual gel-cards remain prevalent in low-resource settings, so multinational suppliers maintain parallel portfolios to serve each regulatory and economic tier.

Recent Industry Insights

The Blood Type Testing industry trends reveal a surge in point-of-care innovation and strategic consolidation. Over the past 18 months, Roche acquired Seqster’s blood-typing algorithms to integrate real-time genomics into its cobas platforms, while Bio-Rad partnered with Grifols to commercialize AI-enhanced gel-cards that cut turnaround time to under 45 seconds. Start-ups are also gaining traction: SanguineDx closed a $31 M Series B for its smartphone-linked rapid test, and TypeSure received FDA 510(k) clearance for the first over-the-counter saliva-based ABO assay, signaling a shift toward consumer-initiated screening. Meanwhile, the EU’s new IVDR (May 2023) has pushed labs to adopt traceable molecular reagents, accelerating the phase-out of manual slide methods. Hospital procurement is favoring bundled contracts that combine type-and-screen with extended antigen panels, driving suppliers to bundle reagents with software subscriptions. With transfusion services under cost pressure, these developments are steering the market from reactive testing to predictive, data-driven blood management.

Analyst Overview

The Blood Type Testing market outlook remains structurally attractive, driven by rising surgical volumes, pre-transfusion safety mandates, and at-home consumer kits. Competitive intensity is moderate; four global IVD giants control ~55% share but niche molecular players are eroding pricing power, compressing average selling prices 3–5% p.a. Long-term growth (6–8% CAGR) is underpinned by emerging-market hospital build-outs and genomic-based extended typing. The innovation landscape is pivoting to microfluidic, sample-to-answer platforms that deliver results in <5 minutes with <10 µL blood, while AI-driven rare antigen matching is gaining traction. Demand–supply is balanced globally, but reagent supply chains for antisera remain vulnerable to bovine spongiform encephalopathy-related import bans. Key risks include tightening reimbursement for high-throughput labs, regulatory divergence between FDA and CE-IVDR, and potential commoditization as patents expire in 2027–2029. Companies that secure dried-blood spot logistics and companion diagnostics partnerships will outgrow the market.

11 items

1. Executive Summary

2. Blood Type Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Blood Type Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Blood Type Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Blood Banks

6.1.3. Clinical Laboratories

6.1.4. Other

6.2. Global Blood Type Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Assay-based Techniques

6.2.2. PCR-based and Microarray Techniques

6.2.3. Massively Parallel Sequencing

6.2.4. Other

6.3. Global Blood Type Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Blood Type Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Blood Type Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Blood Type Testing Market Competition by Key Manufacturers

8.1. Global Blood Type Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Blood Type Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Rad Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. QuidelOrtho

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Grifols, S.A.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Immucor

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. MosaiQ

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Danaher

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. MERCK KGAA

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. BAG Diagnostics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Rapid Labs

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Agena Bioscience

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Biorex Diagnostics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Prestige Diagnostics

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Dialab

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Lorne Labs

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Atlas Medical

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Torax Biosciences

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Fortress Diagnostics

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. AXO Science

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Maxwin Health Care

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. JMitra & Co. Pvt. Ltd.

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Medsource Ozone Biomedicals

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Blood Type Testing Market

Figure 4: Global Blood Type Testing Market: Drivers

Figure 5: Global Blood Type Testing Market: Challenges

Figure 6: Global Blood Type Testing Market: Trends

Figure 7: Global Blood Type Testing Market: Opportunity

Figure 8: Global Blood Type Testing Market: Restraint

Figure 9: Global Blood Type Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Blood Type Testing Market Value (USD Million) By Region

Figure 15: Global Blood Type Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Blood Type Testing Market Value (USD Million) By Region

Figure 23: Global Blood Type Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

97 items

Table 1: Market Segmentation Analysis

Table 2: Global Blood Type Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Blood Type Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Blood Type Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Blood Type Testing Market Value (USD Million) By Region

Table 10: Global Blood Type Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Blood Type Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Blood Type Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Blood Type Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Rad Laboratories Basic Information And Sales Area

Table 31: Bio-Rad Laboratories. Products Portfolio

Table 32: QuidelOrtho Basic Information And Sales Area

Table 33: QuidelOrtho. Products Portfolio

Table 34: Grifols, S.A. Basic Information And Sales Area

Table 35: Grifols, S.A.. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: Immucor Basic Information And Sales Area

Table 39: Immucor. Products Portfolio

Table 40: MosaiQ Basic Information And Sales Area

Table 41: MosaiQ. Products Portfolio

Table 42: Danaher Basic Information And Sales Area

Table 43: Danaher. Products Portfolio

Table 44: MERCK KGAA Basic Information And Sales Area

Table 45: MERCK KGAA. Products Portfolio

Table 46: BAG Diagnostics Basic Information And Sales Area

Table 47: BAG Diagnostics. Products Portfolio

Table 48: Rapid Labs Basic Information And Sales Area

Table 49: Rapid Labs. Products Portfolio

Table 50: Agena Bioscience Basic Information And Sales Area

Table 51: Agena Bioscience. Products Portfolio

Table 52: Biorex Diagnostics Basic Information And Sales Area

Table 53: Biorex Diagnostics. Products Portfolio

Table 54: Prestige Diagnostics Basic Information And Sales Area

Table 55: Prestige Diagnostics. Products Portfolio

Table 56: Dialab Basic Information And Sales Area

Table 57: Dialab. Products Portfolio

Table 58: Lorne Labs Basic Information And Sales Area

Table 59: Lorne Labs. Products Portfolio

Table 60: Atlas Medical Basic Information And Sales Area

Table 61: Atlas Medical. Products Portfolio

Table 62: Torax Biosciences Basic Information And Sales Area

Table 63: Torax Biosciences. Products Portfolio

Table 64: Fortress Diagnostics Basic Information And Sales Area

Table 65: Fortress Diagnostics. Products Portfolio

Table 66: AXO Science Basic Information And Sales Area

Table 67: AXO Science. Products Portfolio

Table 68: Maxwin Health Care Basic Information And Sales Area

Table 69: Maxwin Health Care. Products Portfolio

Table 70: JMitra & Co. Pvt. Ltd. Basic Information And Sales Area

Table 71: JMitra & Co. Pvt. Ltd.. Products Portfolio

Table 72: Medsource Ozone Biomedicals Basic Information And Sales Area

Table 73: Medsource Ozone Biomedicals. Products Portfolio

Table 74: Global Market Value (USD Million) (2025-2032) By Application

Table 75: Global Market Share (%) By Application (2032)

Table 76: Global Market Value (USD Million) (2025-2032) By Types

Table 77: Global Market Share (%) By Types (2032)

Table 78: Global Blood Type Testing Market Value (USD Million) By Region

Table 79: Global Blood Type Testing Market Share (%) By Region (2025-2032)

Table 80: North America Market Value (USD Million) (2025-2032) By Country

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: North America Market Value (USD Million) (2025-2032) By Types

Table 83: Europe Market Value (USD Million) (2025-2032) By Country

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Europe Market Value (USD Million) (2025-2032) By Types

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 89: South America Market Value (USD Million) (2025-2032) By Country

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: South America Market Value (USD Million) (2025-2032) By Types

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 95: Research Programs/Design For This Report

Table 96: Key Data Information From Secondary Sources

Table 97: Key Data Information From Primary Sources

FAQs

1. What is the current Blood Type Testing market size?

Global Blood Type Testing market size surpassed USD 2.1 billion in 2023, underpinned by rising surgical volumes, pre-transfusion protocols, and at-home wellness screening across both developed and emerging economies.

2. What growth is forecast through 2030?

Analysts project an 8.2% CAGR, pushing the Blood Type Testing market past USD 3.6 billion by 2030; molecular typing and point-of-care kits are the fastest-expanding segments within this future outlook.

3. Which factors are driving demand?

Key drivers include escalating surgical procedures, trauma cases, prenatal testing, personalized medicine, and government mandates for 100% pre-transfusion compatibility checks, all amplifying recurring Blood Type Testing market size expansion.

4. What operational challenges restrain growth?

High cost of molecular reagents, shortage of trained lab staff in rural hubs, stringent regulatory validations, and potential transfusion errors from manual entry mistakes collectively temper faster Blood Type Testing market growth.

5. Which regions lead adoption today?

North America commands 42% share via large blood banks and insurance coverage; Europe follows with 28% driven by CE-marked kits; APAC is the quickest-growing region due to expanding healthcare access and voluntary donation campaigns.

6. Who are the top companies?

Market leaders include Bio-Rad, Grifols, Immucor, Quotient, Beckman Coulter, Thermo Fisher, and Danaher; they compete on automated analyzers, CE/FDA portfolios, and strategic blood-bank partnerships that widen Blood Type Testing market share.

7. Where do future opportunities lie?

Growth pockets include decentralized POC devices, AI-driven mismatch prediction, emerging-market blood registries, and companion diagnostics linking ABO antigens to cardiovascular risk, all poised to broaden future outlook.

8. How is technology reshaping testing?

Microarray chips, high-throughput NGS, smartphone-based image readers, and cloud-based result sharing reduce turnaround to under 10 minutes, elevating accuracy and propelling Blood Type Testing market size into new clinical settings.

9. What regulations govern the sector?

FDA 21 CFR 864, EU IVDR 2017/746, and WHO TRS guidelines mandate traceability, unique device identification, post-market surveillance, and risk-class upgrades, shaping product pipelines and compliance budgets across the Blood Type Testing market.

10. How will sustainability trends affect supply chains?

Eco-friendly reagents, recyclable disposables, and energy-efficient analyzers are becoming procurement criteria; vendors adopting green manufacturing can secure tenders and premium pricing, reinforcing long-term Blood Type Testing market growth.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Blood Type Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.65 billion
Revenue forecast in 2033	4.83 billion
Growth rate	CAGR of 7.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad Laboratories; QuidelOrtho; Grifols, S.A.; Thermo Fisher Scientific; Immucor; MosaiQ; Danaher; MERCK KGAA; BAG Diagnostics; Rapid Labs; Agena Bioscience; Biorex Diagnostics; Prestige Diagnostics; Dialab; Lorne Labs; Atlas Medical; Torax Biosciences; Fortress Diagnostics; AXO Science; Maxwin Health Care; JMitra & Co. Pvt. Ltd.; Medsource Ozone Biomedicals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options